Login to Your Account

First antibody directly targeting Ras oncogenes is now developed

By John Fox
Staff Writer

Monday, May 15, 2017

The first therapeutic monoclonal antibody (MAb) that selectively targets activated intracellular cytosolic Ras mutant proteins, which are inaccessible to current antibodies, has been developed and assessed preclinically in a new South Korean study. Performed by scientists at Ajou University in Suwon and Korean biotech company Orum Therapeutics Inc., the study was published in the May 10, 2017, edition of Nature Communications.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription